The US FDA has approved taletrectinib, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). It is a next-generation, highly sensitive oral ROS1 tyrosine kinase inhibitor (TKI) that offers high response rates, sustained benefit, and intracranial activity in advanced ROS1+ NSCLC, with good tolerability. Clinical evidence In a clinical trial involving 103 patients with ROS1 TKI-naïve NSCLC, taletrectinib achieved an overall response rate (ORR) of 90%, with 72% of responders maintaining a duration of response (DOR) of 12 months or longer.
In a separate study of 66 patients with ROS1 TKI-pretreated NSCLC, taletrectinib demonstrated an ORR of 52%, with 74% of responders maintaining a DOR of six months or longer. Dosage and administration Available as capsules Contraindications – None Warnings and precautions Hepatotoxicity Interstitial lung…
